Transcenta Holding’s Chief Executive Officer Dr. Xueming Qian delivered a speech at the 38th Annual J.P. Morgan Healthcare Conference held in San Francisco, US yesterday. He shared with hundreds of invited guests and investors across the world Transcenta’s progress on key assets in the pipeline and the company’s future plans.

Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 million USD series B+ round. CR-CP Life Science Fund ("CR-CP") and Fortune Capital co-led the financing round, participated by new investors including Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, as well as the existing shareholders including Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China, and ARCH Venture Partners. China Renaissance acted as the exclusive financial advisor for this transaction.

Transcenta Holding, a global biotherapeutics company with fully integrated capabilities in the research, development, regulatory affairs and manufacturing of biologics, today announced that its Death Receptor 5 (DR5) Agonist, an innovative antibody internally named as JCT205, has been cleared by the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) to conduct phase I clinical trial in China.

Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China, including the phase 2-completed Blosozumab, a humanized antibody to sclerostin. Transcenta will be responsible for the overall preclinical/clinical development, regulatory filing and manufacture of these biologic therapeutics. As part of this transaction, Lilly will receive an upfront payment in cash plus equity shares in Transcenta, and will be eligible for potential regulatory and sales milestones, and commercial royalty payments.

Transcenta Holding (Transcenta), an innovative biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing, announced today the appointment of Dr. Yi Gu as its Senior Vice President and Head of Research.

HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd., (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of MabSpace, will serve as chief executive officer while Dr. Jonathan Yining Zhao, Co-founder and CEO of HJB, will be the Executive Chairman of the combined company, respectively.

Transcenta Holding’s Chief Executive Officer Dr. Xueming Qian delivered a speech at the 38th Annual J.P. Morgan Healthcare Conference held in San Francisco, US yesterday. He shared with hundreds of invited guests and investors across the world Transcenta’s progress on key assets in the pipeline and the company’s future plans.

Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 million USD series B+ round. CR-CP Life Science Fund ("CR-CP") and Fortune Capital co-led the financing round, participated by new investors including Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, as well as the existing shareholders including Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China, and ARCH Venture Partners. China Renaissance acted as the exclusive financial advisor for this transaction.

Transcenta Holding, a global biotherapeutics company with fully integrated capabilities in the research, development, regulatory affairs and manufacturing of biologics, today announced that its Death Receptor 5 (DR5) Agonist, an innovative antibody internally named as JCT205, has been cleared by the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) to conduct phase I clinical trial in China.

Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China, including the phase 2-completed Blosozumab, a humanized antibody to sclerostin. Transcenta will be responsible for the overall preclinical/clinical development, regulatory filing and manufacture of these biologic therapeutics. As part of this transaction, Lilly will receive an upfront payment in cash plus equity shares in Transcenta, and will be eligible for potential regulatory and sales milestones, and commercial royalty payments.

Transcenta Holding (Transcenta), an innovative biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing, announced today the appointment of Dr. Yi Gu as its Senior Vice President and Head of Research.

HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd., (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of MabSpace, will serve as chief executive officer while Dr. Jonathan Yining Zhao, Co-founder and CEO of HJB, will be the Executive Chairman of the combined company, respectively.